This is a retrospective, case control study aimed to identify risk factors associated with complications in retinoblastoma patients following primary and secondary enucleations with porous implant placements. Patients with retinoblastoma who underwent enucleation with porous orbital implant placement between January 2010 and July 2015 were included. Out of the 103 enucleated eyes of 101 patients diagnosed with retinoblastoma, 70 eyes had primary enucleation and 33 eyes received therapy prior to enucleation. Overall 19 eyes (18.4%) experienced postoperative complications, with an exposure rate of 11.7% overall. Age at enucleation was 24 months or younger. Hispanic ethnicity, female gender and intravenous chemotherapy prior to enucleation were associated with increased odds of implant complications. On the contrary, patients who received intravitreal Melphalan, subtenons Carboplatin or external beam radiotherapy did not demonstrate an increased risk of complications. The average time to complication from the enucleation date is not known. Another limitation is lack of comparison with alternative options such as nonporous implants, and dermis fat graft to manage the anophthalmic sockets post enucleation in this group of patients.